Announcements Trials

Browse Landscape Eligibility

Clinical Trials

0 trials

Recent Start date Enrollment

Mesothelioma, Malignant × spartalizumab × 1 year × Clear all

Sponsor

Conditions

Melanoma 9 Carcinoma, Non-Small-Cell Lung 7 Pancreatic Neoplasms 6 Colorectal Neoplasms 6 Stomach Neoplasms 5 Carcinoma, Renal Cell 5 Uterine Cervical Neoplasms 4 Triple Negative Breast Neoplasms 4 Squamous Cell Carcinoma of Head and Neck 4 Rectal Neoplasms 4 Nasopharyngeal Carcinoma 4 Neoplasm Metastasis 3 Esophageal Neoplasms 3 Endometrial Neoplasms 3 Solid Tumors 2 Solid Tumor 2 Skin Neoplasms 2 Ovarian Neoplasms 2 Neoplasms 2 Myelodysplastic Syndromes 2 Lung Neoplasms 2 Locally Advanced Rectal Cancer 2 Leukemia, Myelomonocytic, Chronic 2 Glioblastoma 2 Esophageal Squamous Cell Carcinoma 2 Breast Neoplasms 2 Advanced Solid Tumors 2 von Hippel-Lindau Disease 1 Thyroid cancer, follicular 1 Thyroid cancer, Hurthle cell 1

Interventions

Cisplatin 15 Pemetrexed 12 pembrolizumab 8 Nivolumab 8 Carboplatin 7 Ipilimumab 5 Cyclophosphamide 5 Platinum 4 1,2-diaminocyclohexaneplatinum II citrate 4 Gemcitabine 3 Drug Therapy 3 tremelimumab 2 fludarabine 2 durvalumab 2 atezolizumab 2 Radiotherapy, Intensity-Modulated 2 Radiotherapy 2 Radiation 2 Photochemotherapy 2 Methotrexate 2 Interleukin-2 2 Chemotherapy, Adjuvant 2 sargramostim 1 olaparib 1 niraparib 1 nintedanib 1 methoxyamine 1 lenvatinib 1 enzalutamide 1 decitabine and cedazuridine drug combination 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

No trials found.

Data powered by HemOnc (CC BY 4.0) Colophon ⚡